Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $8.81 Average Price Target from Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has earned an average recommendation of "Hold" from the nineteen analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, fifteen have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $8.81.

Several equities research analysts have commented on SAGE shares. Bank of America assumed coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 target price on the stock. Wedbush restated a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research report on Wednesday, February 12th. HC Wainwright restated a "neutral" rating and issued a $12.00 price target (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Friday.

Institutional Trading of Sage Therapeutics

Institutional investors have recently made changes to their positions in the stock. Caligan Partners LP acquired a new position in Sage Therapeutics in the fourth quarter valued at $16,575,000. Boothbay Fund Management LLC acquired a new position in shares of Sage Therapeutics in the 4th quarter valued at about $7,540,000. State Street Corp grew its holdings in shares of Sage Therapeutics by 18.2% during the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock worth $21,127,000 after purchasing an additional 451,377 shares during the period. Federated Hermes Inc. increased its position in Sage Therapeutics by 63.7% during the 4th quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company's stock worth $6,004,000 after purchasing an additional 430,432 shares in the last quarter. Finally, Jane Street Group LLC raised its holdings in Sage Therapeutics by 103.1% in the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company's stock valued at $2,509,000 after buying an additional 234,528 shares during the period. 99.22% of the stock is owned by hedge funds and other institutional investors.

Sage Therapeutics Stock Performance

NASDAQ SAGE traded down $0.03 during trading on Tuesday, reaching $7.77. The company's stock had a trading volume of 698,220 shares, compared to its average volume of 1,220,454. The business's fifty day moving average price is $7.51 and its 200-day moving average price is $6.74. The firm has a market cap of $477.40 million, a price-to-earnings ratio of -1.18 and a beta of 0.48. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $14.97.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, sell-side analysts forecast that Sage Therapeutics will post -3.52 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.